StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays reduced their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Cellectis Stock Down 3.5 %

Shares of Cellectis stock opened at $1.91 on Wednesday. The company has a fifty day moving average price of $2.02 and a 200 day moving average price of $2.25. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a twelve month low of $1.70 and a twelve month high of $3.77. The stock has a market cap of $106.17 million, a price-to-earnings ratio of -1.47 and a beta of 3.10.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same period in the previous year, the company earned ($0.31) EPS. Equities research analysts forecast that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Long Focus Capital Management LLC raised its stake in shares of Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares in the last quarter. First Affirmative Financial Network bought a new stake in Cellectis in the third quarter valued at about $45,000. XTX Topco Ltd acquired a new stake in Cellectis during the second quarter valued at approximately $29,000. Finally, Principal Financial Group Inc. lifted its holdings in Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after buying an additional 12,467 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.